A bioactivity-leveling approach for component-specific evaluation in natural product extracts: Optimizing SARS-CoV-2 antiviral screening by controlling for pheophorbide A
PLOS One · 2026
DOI: 10.1371/journal.pone.0355466 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, 2026. Verfasst von Corinna Urmann und 8 weiteren Autor:innen. Beteiligte Einrichtung: Organic-analytical Chemistry, Weihenstephan-Triesdorf University of Applied Sciences, Straubing, Germany. Hauptthemen laut MEDLINE: Antiviral Agents, Plant Extracts, Chlorophyll, Biological Products. Die Arbeit nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Swiss Federal Office for Civil Protection, Spiez Laboratory.
Abstract (Originalsprache)
The emergence of SARS-CoV-2 has intensified the search for novel antiviral agents, with plants representing a promising source due to the documented antiviral properties. Pheophorbides, chlorophyll breakdown products, have been demonstrated to impede viral entry of enveloped viruses. However, the frequent occurrence of pheophorbide A in plant extracts presents a challenge for antiviral screening, as it may obscure the discovery of novel antiviral compounds. The objective of this study was therefore leveling out the influence of pheophorbide A in an in vitro virus pretreatment assay, to prioritize extracts and fractions and support the identification of additional antiviral compounds in plant extracts. Using different experimental derived examples, the limitations and advantages of the strategy presented are discussed. Assay-derived protective effects were interpreted in relation to pheophorbide A quantification, allowing six out of 15 plant species to be prioritized for further investigations. Qualitative comparison of metabolite profiles of fractions with the extent of protective effect supported the prioritization process and led to the identification of candidate compounds potentially contributing to the observed protective effect in Primula veris L. beyond pheophorbide A. Overall, the results highlight the potential value of the proposed strategy for revealing bioactivity beyond known predominant effectors and suggest an applicability in natural product–based screening approaches.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Organic-analytical Chemistry, Weihenstephan-Triesdorf University of Applied Sciences, Straubing, Germany.
- TUM Campus Straubing for Biotechnology and Sustainability, Technical University of Munich, Straubing, Germany.
- Natural Product Chemistry and Phytopharmacy Group, Institute of Chemistry and Biotechnology, School of Life Sciences and Facility Management, ZHAW Zurich University of Applied Sciences, Wädenswil, Switzerland.
- Spiez Laboratory, Federal Office for Civil Protection, Spiez, Switzerland.
ORCID-Profile: Corinna Urmann, Niklas Hofer
Förderung
- Swiss Federal Office for Civil Protection, Spiez Laboratory
Zitieren
APA
Urmann, C., Gmach, Y., Hofer, N., Vahekeni, N., Stehlin, J., Geissmann, Y., Lardos, A., Engler, O., & Wolfram, E. (2026). A bioactivity-leveling approach for component-specific evaluation in natural product extracts: Optimizing SARS-CoV-2 antiviral screening by controlling for pheophorbide A. PLOS One. https://doi.org/10.1371/journal.pone.0355466
Vancouver
Urmann C, Gmach Y, Hofer N, Vahekeni N, Stehlin J, Geissmann Y, et al. A bioactivity-leveling approach for component-specific evaluation in natural product extracts: Optimizing SARS-CoV-2 antiviral screening by controlling for pheophorbide A. PLOS One. 2026. doi:10.1371/journal.pone.0355466
BibTeX
@article{Urmann2026,
author = {Urmann, Corinna and Gmach, Yvonne and Hofer, Niklas and Vahekeni, Nina and Stehlin, Jonas and Geissmann, Yannick and Lardos, Andreas and Engler, Olivier and Wolfram, Evelyn},
title = {A bioactivity-leveling approach for component-specific evaluation in natural product extracts: Optimizing SARS-CoV-2 antiviral screening by controlling for pheophorbide A},
journal = {PLOS One},
year = {2026},
doi = {10.1371/journal.pone.0355466}
}
EUVIMED